TMEM106A

Summary

TMEM106A (transmembrane protein 106A, HGNC:28288) is a protein-coding gene on chromosome 17q21.31, encoding Transmembrane protein 106A (Q96A25). Activates macrophages and polarizes them into M1-like macrophages through the activation of the MAPK and NF-kappaB signaling pathway.

Predicted to be involved in several processes, including positive regulation of intracellular signal transduction; positive regulation of macromolecule biosynthetic process; and positive regulation of nitric oxide metabolic process. Predicted to be located in plasma membrane.

Source: NCBI Gene 113277 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 45 total — 1 pathogenic
• MANE Select transcript: NM_145041

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28288
Approved symbol	TMEM106A
Name	transmembrane protein 106A
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC20235
Ensembl gene	ENSG00000184988
Ensembl biotype	protein_coding
Entrez	113277

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000536052, ENST00000541594, ENST00000586685, ENST00000588659, ENST00000588693, ENST00000592564, ENST00000592649, ENST00000612339, ENST00000876775, ENST00000876776, ENST00000876777, ENST00000876778, ENST00000959741, ENST00000959742, ENST00000959743

RefSeq mRNA: 4 — MANE Select: NM_145041 NM_001291586, NM_001291587, NM_001291588, NM_145041

CCDS: CCDS11462, CCDS74073, CCDS77039

Canonical transcript exons

ENST00000612339 — 9 exons

Exon	Start	End
ENSE00001609329	43211875	43211922
ENSE00001627792	43216449	43216589
ENSE00001673223	43212227	43212394
ENSE00001753477	43217259	43217312
ENSE00001777391	43216697	43216740
ENSE00003523798	43215788	43215941
ENSE00003616329	43213021	43213252
ENSE00003622393	43213828	43213891
ENSE00003741162	43217681	43220041

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 93.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.0225 / max 368.5293, expressed in 1604 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161065	11.9088	1602
161066	0.1136	38

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	93.54	gold quality
renal medulla	UBERON:0000362	89.74	gold quality
pylorus	UBERON:0001166	87.85	gold quality
layer of synovial tissue	UBERON:0007616	87.42	gold quality
monocyte	CL:0000576	84.46	gold quality
tibia	UBERON:0000979	84.22	gold quality
leukocyte	CL:0000738	84.14	gold quality
bone marrow cell	CL:0002092	82.98	gold quality
kidney	UBERON:0002113	82.66	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.23	gold quality
vermiform appendix	UBERON:0001154	82.14	gold quality
parietal pleura	UBERON:0002400	82.12	gold quality
adult mammalian kidney	UBERON:0000082	81.99	gold quality
trachea	UBERON:0003126	81.87	gold quality
adult organism	UBERON:0007023	81.83	gold quality
thymus	UBERON:0002370	81.52	gold quality
visceral pleura	UBERON:0002401	81.38	gold quality
smooth muscle tissue	UBERON:0001135	81.14	gold quality
granulocyte	CL:0000094	80.90	gold quality
caecum	UBERON:0001153	80.64	gold quality
cortex of kidney	UBERON:0001225	80.47	gold quality
blood	UBERON:0000178	80.16	gold quality
dorsal root ganglion	UBERON:0000044	79.81	gold quality
trigeminal ganglion	UBERON:0001675	79.75	gold quality
amniotic fluid	UBERON:0000173	79.69	gold quality
superior surface of tongue	UBERON:0007371	79.67	gold quality
sural nerve	UBERON:0015488	79.59	gold quality
synovial joint	UBERON:0002217	79.55	gold quality
pericardium	UBERON:0002407	79.54	gold quality
lymph node	UBERON:0000029	79.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.28

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

87 targeting TMEM106A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4658	99.77	64.94	514
HSA-MIR-6790-5P	99.77	65.24	505
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-1976	99.74	65.48	1127
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-548AV-5P	99.60	70.84	2107

Literature-anchored findings (GeneRIF, showing 1)

• Low TMEM106A expression is associated with gastric cancer. (PMID:24975047)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tmem106a	ENSMUSG00000034947
rattus_norvegicus	Tmem106a	ENSRNOG00000023628

Protein

Protein identifiers

Transmembrane protein 106A — Q96A25 (reviewed: Q96A25)

All UniProt accessions (3): Q96A25, B7Z779, K7ERE2

UniProt curated annotations — full annotation on UniProt →

Function. Activates macrophages and polarizes them into M1-like macrophages through the activation of the MAPK and NF-kappaB signaling pathway. Upon activation, up-regulates the expression of CD80, CD86, CD69 and MHC II on macrophages, and induces the release of pro-inflammatory cytokines such as TNF, IL1B, IL6, CCL2 and nitric oxide. May play a role in inhibition of proliferation and migration.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in renal cells (at protein level). Expressed in epithelial cells.

Similarity. Belongs to the TMEM106 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96A25-1	1	yes
Q96A25-2	2

RefSeq proteins (4): NP_001278515, NP_001278516, NP_001278517, NP_659478* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009790	TMEM106	Family
IPR048509	TMEM106_C	Domain
IPR048511	TMEM106_N	Domain

Pfam: PF07092, PF21002

UniProt features (3 total): chain 1, transmembrane region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96A25-F1	76.10	0.50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 134 (showing top): GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_INTERLEUKIN_1_PRODUCTION, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GCM_MYCL1, GOBP_POSITIVE_REGULATION_OF_TUMOR_NECROSIS_FACTOR_SUPERFAMILY_CYTOKINE_PRODUCTION, GCM_PRKCG, GCM_RING1, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_MYELOID_LEUKOCYTE_ACTIVATION, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GCM_DPF2, GOBP_CYTOKINE_PRODUCTION, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_1_PRODUCTION

GO Biological Process (11): glycoprotein biosynthetic process (GO:0009101), positive regulation of interleukin-1 beta production (GO:0032731), positive regulation of interleukin-6 production (GO:0032755), positive regulation of tumor necrosis factor production (GO:0032760), macrophage activation (GO:0042116), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), positive regulation of MAPK cascade (GO:0043410), innate immune response (GO:0045087), positive regulation of MHC class II biosynthetic process (GO:0045348), obsolete positive regulation of nitric oxide metabolic process (GO:1904407), immune system process (GO:0002376)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), endomembrane system (GO:0012505), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of intracellular signal transduction	2
cellular anatomical structure	2
macromolecule biosynthetic process	1
glycoprotein metabolic process	1
carbohydrate derivative biosynthetic process	1
interleukin-1 beta production	1
regulation of interleukin-1 beta production	1
positive regulation of interleukin-1 production	1
positive regulation of cytokine production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
myeloid leukocyte activation	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
MAPK cascade	1
regulation of MAPK cascade	1
immune response	1
defense response to symbiont	1
positive regulation of macromolecule biosynthetic process	1
MHC class II biosynthetic process	1
regulation of MHC class II biosynthetic process	1
biological_process	1
binding	1
membrane	1
cell periphery	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

492 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM106A	TAF11L5	A0A1W2PP81	644
TMEM106A	TAF11L4	A0A1W2PPE2	644
TMEM106A	TAF11L3	A0A1W2PRV1	644
TMEM106A	TAF11L2	A6NLC8	572
TMEM106A	A0A1W2PRN6	A0A1W2PRN6	541
TMEM106A	FAM81B	Q96LP2	443
TMEM106A	BST2	Q10589	410
TMEM106A	KREMEN1	Q96MU8	408
TMEM106A	FAM110B	Q8TC76	403
TMEM106A	CLLU1-AS1	Q5K130	399
TMEM106A	ENKUR	Q8TC29	362
TMEM106A	TMEM209	Q96SK2	359
TMEM106A	TMEM229A	B2RXF0	358
TMEM106A	SLFN5	Q08AF3	355
TMEM106A	FAM156A	Q8NDB6	348

IntAct

39 interactions, top by confidence:

A	B	Type	Score
TMEM106A	TMEM106C	psi-mi:“MI:0915”(physical association)	0.670
GOSR2	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
TMEM106A	TNMD	psi-mi:“MI:0915”(physical association)	0.560
IGFBP5	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
GJB2	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
TMEM128	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
ENTPD3	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
TMEM86B	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
TMEM106A	ERG28	psi-mi:“MI:0915”(physical association)	0.560
TMEM107	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
TSPAN4	TMEM106A	psi-mi:“MI:0915”(physical association)	0.560
TMEM106A	B4GALT3	psi-mi:“MI:0914”(association)	0.530
TMEM106A	ARF1	psi-mi:“MI:0915”(physical association)	0.370
TMEM106A	QSOX1	psi-mi:“MI:0914”(association)	0.350
TMEM106A	RTL8C	psi-mi:“MI:0914”(association)	0.350
TMEM106A	TMEM131L	psi-mi:“MI:0914”(association)	0.350
GOSR2	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
TNMD	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
IGFBP5	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
GJB2	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
TSPAN4	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
TMEM106A	TMEM106C	psi-mi:“MI:0915”(physical association)	0.000
TMEM128	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
ENTPD3	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
TMEM86B	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000
ERG28	TMEM106A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (215): TMEM106A (Reconstituted Complex), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TMEM106A (Two-hybrid), TSPAN4 (Two-hybrid), TMEM106A (Negative Genetic), EPHB4 (Affinity Capture-MS), TPST2 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B4J1F4, A6NEK1, G3X9X1, O14972, O15344, O15519, O35075, O70263, O70583, O94955, P82457, P82458, Q2HY40, Q2TBA3, Q32KX1, Q32NJ2, Q497K5, Q4VX76, Q54DI8, Q568M3, Q5M7W1, Q5R5L7, Q5R811, Q5R8Q5, Q5RD56, Q5RDY3, Q5RF33, Q60584, Q62807, Q6TXF1, Q6ZWE6, Q7TP90, Q7TPQ9, Q7ZX59, Q80WG7, Q8BG60, Q8BM47, Q8IY47, Q8NCT1, Q8W4D4

Diamond homologs: Q1LWC2, Q3T144, Q3ZC25, Q5BK83, Q5EA90, Q5RJK0, Q6AYA5, Q80VP8, Q80X71, Q8VC04, Q96A25, Q9BVX2, Q9NUM4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	34
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1713241	NC_000017.10:g.41221355_41380248del	Pathogenic

SpliceAI

1472 predictions. Top by Δscore:

Variant	Effect	Δscore
17:43213019:A:AG	acceptor_gain	1.0000
17:43213020:G:GG	acceptor_gain	1.0000
17:43213020:GT:G	acceptor_gain	1.0000
17:43215861:C:CA	acceptor_gain	1.0000
17:43215918:GCTGA:G	donor_gain	1.0000
17:43215942:GTGG:G	donor_gain	1.0000
17:43216448:GA:G	acceptor_gain	1.0000
17:43216448:GAAT:G	acceptor_gain	1.0000
17:43216696:GAT:G	acceptor_gain	1.0000
17:43216738:ATA:A	donor_gain	1.0000
17:43216739:TA:T	donor_gain	1.0000
17:43216741:G:GG	donor_gain	1.0000
17:43217258:GCAAA:G	acceptor_gain	1.0000
17:43217313:G:GG	donor_gain	1.0000
17:43213019:AGT:A	acceptor_gain	0.9900
17:43213020:GTG:G	acceptor_gain	0.9900
17:43213020:GTGAA:G	acceptor_gain	0.9900
17:43213826:A:AG	acceptor_gain	0.9900
17:43213827:G:GG	acceptor_gain	0.9900
17:43213827:GA:G	acceptor_gain	0.9900
17:43213827:GAGCT:G	acceptor_gain	0.9900
17:43213892:G:GG	donor_gain	0.9900
17:43215938:AACG:A	donor_loss	0.9900
17:43216445:CCAGA:C	acceptor_loss	0.9900
17:43216446:CA:C	acceptor_loss	0.9900
17:43216447:A:AC	acceptor_loss	0.9900
17:43216447:A:AG	acceptor_gain	0.9900
17:43216448:G:GA	acceptor_gain	0.9900
17:43216448:GAA:G	acceptor_gain	0.9900
17:43216448:GAATA:G	acceptor_gain	0.9900

AlphaMissense

1707 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:43213855:T:C	I80T	0.973
17:43217266:T:C	C208R	0.972
17:43215819:T:C	C103R	0.971
17:43217268:T:G	C208W	0.970
17:43217751:T:A	C247S	0.970
17:43217752:G:C	C247S	0.970
17:43217266:T:A	C208S	0.968
17:43217267:G:C	C208S	0.968
17:43217682:G:C	G224R	0.968
17:43217267:G:A	C208Y	0.967
17:43217689:T:C	L226P	0.964
17:43217751:T:C	C247R	0.964
17:43217753:C:G	C247W	0.958
17:43216469:T:A	N150K	0.957
17:43216469:T:G	N150K	0.957
17:43216501:T:C	L161P	0.954
17:43213855:T:G	I80S	0.950
17:43217752:G:A	C247Y	0.947
17:43213216:T:C	C59R	0.946
17:43217683:G:A	G224D	0.945
17:43213874:G:C	R86S	0.944
17:43213874:G:T	R86S	0.944
17:43215931:T:C	L140P	0.942
17:43216475:C:A	N152K	0.942
17:43216475:C:G	N152K	0.942
17:43213876:T:C	L87P	0.940
17:43216456:T:C	L146S	0.940
17:43213855:T:A	I80N	0.938
17:43217727:T:C	F239L	0.931
17:43217729:T:A	F239L	0.931

dbSNP variants (sampled 300 via entrez): RS1000105420 (17:43218586 G>A), RS1000136495 (17:43218897 C>T), RS1000902714 (17:43211013 T>C), RS1001356619 (17:43211313 T>C), RS1001576724 (17:43214263 G>A,C), RS1001918905 (17:43212537 C>A,T), RS1001961765 (17:43218201 C>G,T), RS1002237114 (17:43211383 G>A), RS1002374664 (17:43219696 C>T), RS1003513529 (17:43212678 T>A), RS1003577998 (17:43212307 G>A,T), RS1003637719 (17:43219849 C>G,T), RS1004886863 (17:43213749 C>A,T), RS1004939273 (17:43214082 G>A), RS1005613838 (17:43217583 A>G)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:604370

GenCC curated gene-disease

Mondo (2): breast-ovarian cancer, familial, susceptibility to, 1 (MONDO:0011450), neuromuscular disease (MONDO:0019056)

Orphanet (2): Hereditary breast and/or ovarian cancer syndrome (Orphanet:145), Neuromuscular disease (Orphanet:68381)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_2771	Blood protein levels	9.000000e-08

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009468	Neuromuscular Diseases	C10.668

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression	2
Estradiol	decreases expression	2
Nickel	increases expression	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
Particulate Matter	increases abundance, increases expression, affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	increases expression	1
methylmercuric chloride	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
hydroquinone	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
ICG 001	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Cadmium	decreases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Lead	increases expression	1
Polycyclic Aromatic Hydrocarbons	increases abundance, affects cotreatment, decreases expression	1
Quercetin	decreases expression	1
Silicon Dioxide	increases expression	1
Thiram	increases expression	1
Zinc	increases expression	1

Clinical trials (associated diseases)

198 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00331656	PHASE4	UNKNOWN	Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure.
NCT00994552	PHASE4	UNKNOWN	Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure
NCT00839033	PHASE3	TERMINATED	Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
NCT00942227	PHASE3	COMPLETED	The Value of Traction in Treatment of Lumbar Radiculopathy
NCT00979108	PHASE3	COMPLETED	The Value of Traction in the Treatment of Cervical Radiculopathy
NCT01826487	PHASE3	COMPLETED	Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
NCT02090959	PHASE3	TERMINATED	An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
NCT02436096	PHASE3	COMPLETED	A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
NCT02829814	PHASE3	TERMINATED	Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
NCT03179631	PHASE3	COMPLETED	Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
NCT05126758	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05156320	PHASE3	COMPLETED	Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
NCT05337553	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05626855	PHASE3	ACTIVE_NOT_RECRUITING	Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT06672237	PHASE3	RECRUITING	A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT01074359	PHASE2	TERMINATED	Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation
NCT01371149	PHASE2	COMPLETED	Patient -Ventilator Interaction in Chronic Respiratory Failure
NCT02022072	PHASE2	TERMINATED	Evaluation of Vital Capacity
NCT03127514	PHASE2	COMPLETED	AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03406780	PHASE2	COMPLETED	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT03921528	PHASE2	COMPLETED	An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
NCT05479981	PHASE2	COMPLETED	Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
NCT06339580	PHASE2	RECRUITING	Assessment of Volume-targeted Ventilation in Patients With Neuromuscular Disease
NCT07071935	PHASE2	NOT_YET_RECRUITING	A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
NCT07287189	PHASE2	RECRUITING	Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT00252252	PHASE1	COMPLETED	AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation
NCT01560741	PHASE1	UNKNOWN	Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation
NCT01621984	PHASE1	COMPLETED	Therapeutic Riding and Neuromuscular Disease
NCT01758510	PHASE1	COMPLETED	Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
NCT03440034	PHASE1	COMPLETED	Study of Pioglitazone in Sporadic Inclusion Body Myositis
NCT05730842	PHASE1	COMPLETED	Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
NCT03272802	PHASE2/PHASE3	UNKNOWN	Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00860951	PHASE1/PHASE2	COMPLETED	P300 Brain Computer Interface Keyboard to Operate Assistive Technology
NCT02362425	PHASE1/PHASE2	COMPLETED	Antioxidant Therapy in RYR1-Related Congenital Myopathy
NCT00001201	Not specified	COMPLETED	Evaluation of Neuromuscular Disease
NCT00002044	Not specified	COMPLETED	A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
NCT00004553	Not specified	COMPLETED	Electromyography to Diagnose Neuromuscular Disorders
NCT00015470	Not specified	COMPLETED	Diagnostic Evaluation of Patients With Neuromuscular Disease
NCT00017745	Not specified	COMPLETED	Phenotype/Genotype Correlations in Neuromuscular Disorders
NCT00695591	Not specified	COMPLETED	Home Sleep Testing in Neuromuscular Disease Patients